Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Food on Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
NCT05101148Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of selumetinib in neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN), sponsored by AstraZeneca. Primary endpoints: Area under the plasma concentration-time curve from zero to 12 hours post-dose, Gastrointestinal Adverse Events and 4 more. Started Jul 2021; status: active, not recruiting.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on NCT05101148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05101148.